Page 128 - The Indian Optician Digital Edition May-Junel 2022

Table 3: Breakup of positive slides showing inclusion bodies
Total no. of No. of elementary No. of initial bodies No. of bodies that could not
positive cases bodies be differentiated
AO 21 17 (80.9%) 4 (1.1%) 0

Giemsa 18 11 (61.1%) 1 (5.6%) (33.3%)

cytoplasm. Out of the total 50 cases, elementary Whereas, the inclusion bodies with Giemsa were
or initial bodies were seen in 21 cases with AO not easily identifiable because of minimal colour
while with Giemsa they were seen in 18 cases. contrast between the inclusion bodies and the
AO was also better at detecting the elementary cytoplasm.
bodies, detection being 80.9% with AO and
61.1% with Giemsa. It was found that more At first, trachoma may cause mild itching and
number of cases were positive in the grades I irritation of your eyes and eyelids. Then you may
and II of Trachoma. notice swollen eyelids and pus draining from the
eyes. Untreated trachoma can lead to blindness.
It was also seen that among the patients
having chronic conjunctivitis, 4 out of 10 cases STAGE 4 TRACHOMA
unexpectedly showed the presence of inclusion
bodies with Acridine Orange and 3 out of 10
cases with Giemsa stain. Chi square test was
used to test the significance of difference
between the two and was found to be 0.26.

Conclusion: AO stain had definite
advantages over Giemsa stain. However, the
difference between the two, was not found to
be significant, statistically. Inclusion bodies
were immediately and easily identified with AO
staining because of their bright fluorescence.

Table 4: Percentage of positive cases in different grades of Trachoma
Grade of Trachoma Total cases Positive smears
AO stain Giemsa stain
I 10 6 (60%) 5 (50%)
II 6 4 (66.6%) 4 (66.6%)

III 10 5 (50%) 4 (40%)
IV 4 1 (25%) 1 (25%)

Patients who were under treatment or had taken previous treatment showed negative results

Grade of Total no. of cases Cytological negative Under treatment Previous treatment
Trachoma cases
I 10 4 4 -

II 6 2 2 -
III 10 5 1 4
IV 4 3 - 3

124 THE INDIAN OPTICIAN MAY-JUNE 2022 CASE STUDY